Cargando…

Alendronate reduces periosteal microperfusion in vivo

OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundert, Danielle N., Tavassol, Frank, Kampmann, Andreas, Gellrich, Nils-Claudius, Lindhorst, Daniel, Precht, Marc M., Schumann, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481298/
https://www.ncbi.nlm.nih.gov/pubmed/37681156
http://dx.doi.org/10.1016/j.heliyon.2023.e19468
_version_ 1785101947270856704
author Kundert, Danielle N.
Tavassol, Frank
Kampmann, Andreas
Gellrich, Nils-Claudius
Lindhorst, Daniel
Precht, Marc M.
Schumann, Paul
author_facet Kundert, Danielle N.
Tavassol, Frank
Kampmann, Andreas
Gellrich, Nils-Claudius
Lindhorst, Daniel
Precht, Marc M.
Schumann, Paul
author_sort Kundert, Danielle N.
collection PubMed
description OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. STUDY DESIGN: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. RESULTS: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm(2), two weeks alendronate treatment 44.77 ± 3.55 cm/cm(2), six weeks alendronate treatment 27.54 ± 2.23 cm/cm(2)) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. CONCLUSION: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ.
format Online
Article
Text
id pubmed-10481298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104812982023-09-07 Alendronate reduces periosteal microperfusion in vivo Kundert, Danielle N. Tavassol, Frank Kampmann, Andreas Gellrich, Nils-Claudius Lindhorst, Daniel Precht, Marc M. Schumann, Paul Heliyon Research Article OBJECTIVES: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. STUDY DESIGN: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. RESULTS: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm(2), two weeks alendronate treatment 44.77 ± 3.55 cm/cm(2), six weeks alendronate treatment 27.54 ± 2.23 cm/cm(2)) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. CONCLUSION: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ. Elsevier 2023-08-25 /pmc/articles/PMC10481298/ /pubmed/37681156 http://dx.doi.org/10.1016/j.heliyon.2023.e19468 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Kundert, Danielle N.
Tavassol, Frank
Kampmann, Andreas
Gellrich, Nils-Claudius
Lindhorst, Daniel
Precht, Marc M.
Schumann, Paul
Alendronate reduces periosteal microperfusion in vivo
title Alendronate reduces periosteal microperfusion in vivo
title_full Alendronate reduces periosteal microperfusion in vivo
title_fullStr Alendronate reduces periosteal microperfusion in vivo
title_full_unstemmed Alendronate reduces periosteal microperfusion in vivo
title_short Alendronate reduces periosteal microperfusion in vivo
title_sort alendronate reduces periosteal microperfusion in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481298/
https://www.ncbi.nlm.nih.gov/pubmed/37681156
http://dx.doi.org/10.1016/j.heliyon.2023.e19468
work_keys_str_mv AT kundertdaniellen alendronatereducesperiostealmicroperfusioninvivo
AT tavassolfrank alendronatereducesperiostealmicroperfusioninvivo
AT kampmannandreas alendronatereducesperiostealmicroperfusioninvivo
AT gellrichnilsclaudius alendronatereducesperiostealmicroperfusioninvivo
AT lindhorstdaniel alendronatereducesperiostealmicroperfusioninvivo
AT prechtmarcm alendronatereducesperiostealmicroperfusioninvivo
AT schumannpaul alendronatereducesperiostealmicroperfusioninvivo